Management of Psoriasis

Initial Evaluation

• The American Academy of Dermatology recommends that the initial treatment for a first psoriasis flare-up is the use of moderate to high potency topical corticosteroids (classes 2 to 5) for a maximum of 4 weeks for plaques not affecting intertriginous areas 1
• The assessment of severity should include the patient's perception of their disability (need for treatment) and an objective assessment of the extent and severity of skin involvement, as suggested by the British Medical Journal 2
• The diagnosis of psoriasis is clinical and usually does not require complementary examinations, according to the British Medical Journal 2
• It is essential to recognize psoriasis as a chronic multisystem inflammatory disorder to optimize management and reduce comorbidities, as recommended by the American Academy of Dermatology 1

Topical Treatment

• For psoriasis plaques not affecting intertriginous areas, the American Academy of Dermatology recommends using corticosteroids of class 2 to 5 (moderate to high potency) for a maximum of 4 weeks 1
• For the scalp, the American Academy of Dermatology recommends topical corticosteroids of class 1 to 7 for at least 4 weeks 1
• The British Medical Journal suggests that corticosteroids of class 1 (very potent) should be used under dermatological supervision 2
• The American Academy of Dermatology recommends using lower potency corticosteroids on the face, intertriginous areas, and sensitive areas to avoid skin atrophy 1

Precautions and Alternatives

• The British Medical Journal recommends regular clinical follow-up when using topical corticosteroids 2
• The British Medical Journal advises against prescribing renewals without medical supervision 2
• The British Medical Journal suggests not exceeding 100g of a moderate potency preparation per month 2
• The British Medical Journal recommends planning annual periods where an alternative treatment is used 2
• The American Academy of Dermatology recommends using vitamin D analogs (calcipotriol) alone or in combination with corticosteroids for a synergistic effect 3
• The American Academy of Dermatology suggests using combined products with calcipotriol and corticosteroids for the treatment of psoriasis 3
• The British Medical Journal recommends using coal tar as an alternative treatment, starting with concentrations of 0.5-1.0% and gradually increasing up to 10% 2
• The American Academy of Dermatology recommends using tazarotene (topical retinoid) in combination with moderate to high potency topical corticosteroids 3

Important Considerations

• The treatment is suppressive, aiming to induce remission or make psoriasis tolerable for the patient, as stated by the British Medical Journal 2
• Relapses are difficult to predict and cannot be avoided with topical therapeutic agents, according to the British Medical Journal 2
• For unclear reasons, some patients who do not respond to one topical agent will respond to another, as suggested by the British Medical Journal 2
• The American Academy of Dermatology recommends avoiding the use of systemic corticosteroids as they can precipitate or worsen psoriasis flare-ups, especially when stopped 4

Referral to a Specialist

• The British Medical Journal suggests that most patients with chronic stable plaque psoriasis and guttate psoriasis can be managed by general practitioners 2
• Patients with severe psoriasis requiring systemic agents should be followed by a dermatologist due to the potential toxicity of these medications, as recommended by the British Medical Journal 2

Medications to Avoid

• The British Medical Journal recommends avoiding alcohol, and in some patients, beta-blockers and non-steroidal anti-inflammatory drugs, as they can worsen psoriasis 2
• The British Medical Journal advises against using lithium, chloroquine, and mepacrine, as they can be associated with severe, potentially fatal, psoriasis deterioration 2
• The American Academy of Dermatology recommends avoiding the simultaneous use of salicylic acid with calcipotriol, as the acidic pH will inactivate calcipotriol and reduce its effectiveness 3

First-Line Treatment for Psoriasis

Topical Therapies

• Vitamin D analogs (calcipotriene/calcipotriol) combined with topical corticosteroids provide a synergistic effect and are more effective than either agent alone, as recommended by the American Academy of Dermatology 5, 6
• A popular regimen is dual therapy with high/ultra-high potency topical steroid and topical vitamin D analogue, either as separate products or as a fixed combination product, according to the American Academy of Dermatology 7, 5
• Tazarotene (topical retinoid) is effective when combined with moderate to high potency topical corticosteroids, which helps reduce irritation while enhancing efficacy, as per the American Academy of Dermatology 5, 6
• Topical calcineurin inhibitors (tacrolimus 0.1%) are recommended for psoriasis of the face, genitalia, and body folds as they don't cause skin atrophy, as suggested by the American Academy of Dermatology 7

Treatment Algorithm for Localized Psoriasis

• For maintenance, consider weekend-only application of corticosteroids while using vitamin D analogs on weekdays, as recommended by the American Academy of Dermatology 7, 5
• For face and intertriginous areas, use low potency corticosteroids or topical calcineurin inhibitors, according to the American Academy of Dermatology 7

Systemic Therapy

• For moderate to severe psoriasis (>5% body surface area) or inadequate response to topical therapy, systemic therapies including methotrexate, acitretin, or cyclosporine should be considered, as per the European League Against Rheumatism 8

Special Considerations

• Perceived "tachyphylaxis" to topical corticosteroids is often due to poor patient adherence rather than receptor down-regulation, as noted by the American Academy of Dermatology 5, 6

First‑Line Topical Therapy for Limited‑Area Plaque Psoriasis

Recommended Combination Regimen

• Moderate‑to‑high potency topical corticosteroids (classes 2‑5) combined with a vitamin D analog (calcipotriene) are strongly recommended as the first‑line treatment for limited‑area plaque psoriasis, with a maximum duration of 4 weeks. [9][10]

Efficacy of Fixed‑Combination Products

• Fixed‑combination preparations of calcipotriene with betamethasone dipropionate provide convenient once‑daily application and represent the most extensively studied and efficacious topical option for limited‑area disease. 11
• Dual therapy (corticosteroid + calcipotriene) yields superior clearance compared with either agent alone, with clinical improvement typically evident within 2 weeks and maximal response by 4 weeks in most patients. 11

Maintenance to Minimize Steroid‑Induced Atrophy

• After achieving initial control, transition to weekend‑only corticosteroid application while continuing the vitamin D analog on the remaining five days of the week to preserve efficacy and reduce the risk of skin atrophy. 11

Modifications for Sensitive Anatomical Sites

• For facial, genital, and intertriginous regions, employ low‑potency corticosteroids or topical calcineurin inhibitors (e.g., tacrolimus 0.1 %) to avoid atrophic changes. [9][10]
• Calcitriol, an active vitamin D metabolite, is less irritating than other vitamin D analogs and is better tolerated on sensitive skin such as the face and flexural areas. 11

Alternative First‑Line Options

• Topical tazarotene combined with moderate‑to‑high potency corticosteroids reduces irritation, enhances overall efficacy, and can prolong remission periods. 11
• 308‑nm excimer laser or other targeted phototherapy modalities may be employed for localized plaques that are resistant to standard topical regimens, allowing selective treatment while sparing surrounding healthy skin. 11

Safety Limits for Vitamin D Analogs

• Limit the total amount of vitamin D analog applied to no more than 100 g per week to prevent the risk of hypercalcemia. 11